Finch Therapeutics Group (NASDAQ:FNCH) Shares Down 5.1%

Posted by James Quigley on Apr 20th, 2024

Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report)’s share price fell 5.1% on Friday . The stock traded as low as $2.16 and last traded at $2.24. 29,863 shares were traded during trading, an increase of 5% from the average session volume of 28,534 shares. The stock had previously closed at $2.36.

Finch Therapeutics Group Stock Performance

The firm has a 50 day simple moving average of $2.53 and a two-hundred day simple moving average of $3.24. The stock has a market cap of $3.61 million, a P/E ratio of -0.05 and a beta of 0.46.

Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) last announced its earnings results on Monday, March 25th. The company reported ($1.89) earnings per share for the quarter.

Institutional Trading of Finch Therapeutics Group

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Finch Therapeutics Group by 2.3% in the 1st quarter. BlackRock Inc. now owns 404,931 shares of the company’s stock worth $2,038,000 after buying an additional 9,149 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Finch Therapeutics Group by 202.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,900 shares of the company’s stock worth $59,000 after buying an additional 82,300 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Finch Therapeutics Group in the 2nd quarter worth $259,000. Vanguard Group Inc. raised its stake in shares of Finch Therapeutics Group by 10.0% in the 3rd quarter. Vanguard Group Inc. now owns 35,939 shares of the company’s stock worth $186,000 after buying an additional 3,263 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Finch Therapeutics Group in the 2nd quarter worth $98,000. Institutional investors own 21.77% of the company’s stock.

Finch Therapeutics Group Company Profile

(Get Free Report)

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease.